Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase Family: Novel Prognostic Biomarkers and Tumor Microenvironment Regulators for Lower-Grade Glioma.
PLOD family
immune infiltration
immunotherapy
lower-grade glioma
prognosis
tumor microenvironment
Journal
Frontiers in cellular neuroscience
ISSN: 1662-5102
Titre abrégé: Front Cell Neurosci
Pays: Switzerland
ID NLM: 101477935
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
12
2021
accepted:
24
01
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Lower-grade glioma (LGG) is a group of tumors arising from the cells of the central nervous system. Although various therapy interventions are used, the prognosis remains different. Novel biomarkers are needed for the prognosis of disease and novel therapeutic strategies in LGG. The procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD) family contains three members and is related to multiple cancers, yet it was not investigated in LGG. Data from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) cohorts were used to analyze the role of PLOD in LGG. As the PLOD family is involved in processes, such as tumor formation and cancer metastasis, we focused on its relationship to the tumor microenvironment (TME) in LGG. A high expression of the PLOD family relates to poor prognosis and high infiltration of immune cells within the TME. The expression level of the PLOD family might become a novel biomarker for prognosis and is a potential target for individual treatment decisions in LGG.
Identifiants
pubmed: 35250490
doi: 10.3389/fncel.2022.838548
pmc: PMC8894330
doi:
Types de publication
Journal Article
Langues
eng
Pagination
838548Informations de copyright
Copyright © 2022 Gong, Wu, Köhler, Meixensberger, Schopow and Kallendrusch.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Matrix Biol. 2019 Aug;81:91-106
pubmed: 30463024
Science. 2017 Jun 23;356(6344):
pubmed: 28546318
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Trends Immunol. 2007 Jan;28(1):12-8
pubmed: 17129764
Cell Tissue Res. 2016 Sep;365(3):495-506
pubmed: 27461257
Sci Rep. 2021 Aug 26;11(1):17170
pubmed: 34446747
J Cancer. 2020 Jan 1;11(1):121-131
pubmed: 31892979
Nat Commun. 2020 Nov 26;11(1):6170
pubmed: 33243989
Front Immunol. 2020 Dec 21;11:606164
pubmed: 33408717
Nat Rev Immunol. 2011 Oct 10;11(11):762-74
pubmed: 21984070
Acta Neuropathol Commun. 2020 Dec 11;8(1):221
pubmed: 33308315
J Immunol. 2011 Nov 15;187(10):5452-62
pubmed: 21998458
PeerJ. 2021 May 14;9:e11422
pubmed: 34040895
Front Mol Neurosci. 2019 Nov 21;12:282
pubmed: 31824260
Science. 2017 Mar 31;355(6332):
pubmed: 28360267
Glia. 2002 Nov;40(2):252-9
pubmed: 12379912
Nat Immunol. 2016 Jul;17(7):797-805
pubmed: 27135602
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Ann Neurol. 2021 Jan;89(1):13-23
pubmed: 33091175
Brain. 2007 Apr;130(Pt 4):1089-104
pubmed: 17438020
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Nat Immunol. 2017 Feb;18(2):123-131
pubmed: 28092374
Clin Cancer Res. 2011 Jan 15;17(2):317-27
pubmed: 21224364
Biochim Biophys Acta. 2009 Apr;1788(4):842-57
pubmed: 19061857
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1540-E1549
pubmed: 29386395
J Neurooncol. 2016 Nov;130(2):269-282
pubmed: 27174197
J Immunol. 2007 Jul 15;179(2):845-53
pubmed: 17617575
Clin Cancer Res. 2020 Oct 15;26(20):5287-5296
pubmed: 32527943
Cell Rep. 2017 Oct 31;21(5):1399-1410
pubmed: 29091775
Genomics Proteomics Bioinformatics. 2021 Feb;19(1):1-12
pubmed: 33662628
Front Cell Neurosci. 2018 Jul 10;12:193
pubmed: 30042661
Am Soc Clin Oncol Educ Book. 2019 Jan;39:133-145
pubmed: 31099638
Biomed Res Int. 2020 Oct 19;2020:3418398
pubmed: 33134376
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Brain. 2017 Mar 1;140(3):527-546
pubmed: 27794524
Neuro Oncol. 2018 Jan 10;20(1):55-65
pubmed: 28651374
Mol Oncol. 2018 Jun;12(7):1188-1202
pubmed: 29754406
Neurosurg Clin N Am. 2019 Jan;30(1):111-118
pubmed: 30470398
Cancer Res. 2020 Apr 1;80(7):1498-1511
pubmed: 32041837
Cell. 2018 Sep 20;175(1):85-100.e23
pubmed: 30173916
Mol Oncol. 2017 Jul;11(7):805-823
pubmed: 28599100
J BUON. 2021 Jul-Aug;26(4):1556-1562
pubmed: 34565019
Cancer. 2017 Dec 1;123(23):4535-4546
pubmed: 28980701
J Cell Biol. 2001 Feb 5;152(3):545-52
pubmed: 11157981
Cancer Immunol Res. 2019 May;7(5):737-750
pubmed: 30842092
Front Cell Dev Biol. 2018 Jun 28;6:66
pubmed: 30003082
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6834-6847
pubmed: 32633376
Cancers (Basel). 2021 Nov 21;13(22):
pubmed: 34830998
J Pak Med Assoc. 2017 May;67(5):816-817
pubmed: 28507382
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Cancers (Basel). 2021 Feb 25;13(5):
pubmed: 33668819
Cancer Immunol Res. 2019 Dec;7(12):1928-1943
pubmed: 31530559
Cancers (Basel). 2019 Nov 21;11(12):
pubmed: 31766574
Genomics. 1994 Dec;24(3):464-71
pubmed: 7713497
Nat Commun. 2013;4:2612
pubmed: 24113773
J Neuroimmune Pharmacol. 2013 Sep;8(4):763-73
pubmed: 23740386
Front Oncol. 2020 Sep 04;10:1695
pubmed: 33014843
Eur J Neurosci. 1999 Oct;11(10):3648-58
pubmed: 10564372
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Genome Biol. 2017 Dec 20;18(1):234
pubmed: 29262845
Curr Opin Neurol. 2015 Dec;28(6):633-938
pubmed: 26397230
Int J Mol Sci. 2021 Sep 14;22(18):
pubmed: 34576068
Theranostics. 2018 Sep 09;8(17):4733-4749
pubmed: 30279734